Here are 1-2 brief analogies for Conexeu Sciences (CNXU):

• An early-stage Organogenesis focused on developing a new type of collagen-based regenerative tissue for wound care.
• Like an early-stage Integra LifeSciences developing a novel regenerative medical device for tissue repair.

• CXU™ scaffold device candidate: A temperature-responsive, collagen-based extracellular matrix (ECM) formulation designed to transition from a liquid to a gel-like scaffold for regenerative tissue applications.

Based on the provided company description, Conexeu Sciences (CNXU) is an early-stage medical device company with its only device candidate, CXU™ scaffold, currently in preclinical development. The device has not been approved or cleared for marketing in any jurisdiction, and the company is still conducting preclinical research and preparing for regulatory engagement.

Therefore, Conexeu Sciences does not currently have any major customers, as its products are not yet commercially available.

Miles Harrison
President & Chief Executive Officer

Mr. Harrison was appointed President and Chief Executive Officer of Conexeu Sciences in November 2025. He is a healthcare and aesthetics executive with a history of scaling global businesses, driving innovation, and creating shareholder value. Previously, Mr. Harrison co-founded and led Novaestiq Corp., building a novel aesthetics platform and positioning it for a significant strategic exit in 2025, with Novaestiq Corp. being acquired by Waldencast plc. Before Novaestiq, he served as President & General Manager, North America at Galderma, leading three business units across North America and supporting EQT's multi-billion dollar acquisition of Galderma in late 2019. Earlier in his career, he built the U.S. Consumer Business Unit at Nestlé Skin Health from the ground up. Mr. Harrison currently serves on the Board of Castle Biosciences (NASDAQ: CSTL).

Steve Inouye
Chief Financial Officer, Corporate Secretary and Treasurer

Mr. Inouye was appointed Chief Financial Officer for Conexeu Sciences in November 2023, and subsequently also assumed the positions of Secretary and Treasurer in April 2025. He is a financial executive with nearly 40 years of experience, primarily focused on accounting and tax management, while also providing strategic guidance to both private and publicly held companies. Mr. Inouye co-founded a Canadian biotech company that developed bio-pharmaceutical products and possesses deep expertise in small-cap markets, securities regulations, and corporate governance. He has managed audits for multiple go-public transactions, supporting capital raises and growth initiatives.

Dr. Claudia Chavez-Munoz, MD, PhD
Chief Scientific Officer, Co-Founder

Dr. Chavez-Munoz is a distinguished surgeon-scientist, internationally recognized for her pioneering work in burn care, wound healing, and tissue regeneration. She is a co-founder of Conexeu Sciences, established in 2023, and currently serves as Chief Scientific Officer, leading innovation in regenerative therapeutics. Prior to her current role, Dr. Chavez-Munoz served as the company's Chief Medical Officer from October 2023 to April 2025.

Dr. Brian Pilcher, PhD
Chief Medical Officer

Dr. Pilcher was appointed Chief Medical Officer for Conexeu Sciences in April 2025.

Sonia Thomas, MBA
Head of Strategy & Transformation

Ms. Thomas brings over 20 years of experience in operational excellence, brand development, M&A integration, finance, and commercial growth, with a background spanning Fortune 500 and global healthcare organizations. Her experience includes multiple positions at Galderma in Marketing, Finance, Project Management, Launch Excellence, and Commercial Strategy. Her earlier career involved leadership roles in audit, finance, integration, and operations across financial services and investment banking.

1. Regulatory Approval and Commercialization Uncertainty for its Sole Product Candidate: Conexeu Sciences faces significant uncertainty regarding the regulatory approval and commercialization of its only device candidate, the CXU™ scaffold device. The device is currently in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The U.S. Food and Drug Administration (FDA) has not yet determined the appropriate classification or regulatory pathway for the device candidate, may require additional data or a different pathway, and there is no assurance that the company will obtain clearance or that the device candidate will become commercially available.

2. Sole Reliance on a Single Device Candidate: The company's business is entirely dependent on the successful development and commercialization of its CXU™ scaffold device candidate. The provided information explicitly states that "The Company's only device candidate is the CXU™ scaffold device candidate". This means that if the CXU™ device fails to achieve regulatory approval, commercial viability, or market acceptance, the company currently has no other product in its pipeline to pursue, posing a significant risk to its future operations and success.

• The U.S. advanced wound care market was valued at approximately USD 5.3 billion in 2025 and is projected to reach USD 8.6 billion by 2034.
• The wound healing segment of the global regenerative medicine market was estimated at USD 10.32 billion in 2024 and is projected to grow to approximately USD 36.84 billion by 2030. North America is a dominant region in the regenerative medicine market, holding over 48% market share in 2025.

Here are the expected drivers of future revenue growth for Conexeu Sciences (CNXU) over the next 2-3 years:

1. Successful attainment of U.S. Food and Drug Administration (FDA) 510(k) clearance for the CXU™ scaffold device.
2. Initial commercialization and market introduction of the CXU™ scaffold device in the U.S. wound care market.
3. Expansion into additional medical applications for the CXU™ scaffold device beyond initial wound care uses.
4. Geographic market expansion of the CXU™ scaffold device into territories outside the United States.

Share Repurchases

• Conexeu Sciences has not made any share repurchases.

Share Issuance

• On May 12, 2026, Conexeu Sciences issued 4,342,648 shares of common stock upon the exercise of outstanding warrants, resulting in gross proceeds of approximately $1.96 million.
• In 2025, the company issued 3,750,000 shares through a private placement that closed on May 16, 2025, and 397,789 shares from a Regulation Crowdfunding (Reg CF) offering completed in September or October 2025.
• In September 2024, 750,000 shares of common stock were issued as part of a debt settlement agreement.

Inbound Investments

• Conexeu Sciences completed a $5 million Regulation Crowdfunding (Reg CF) financing in October 2025.
• Approximately $7 million was deployed developing the company's technology over more than a decade, including funds from universities, government grants, and existing shareholders.

Capital Expenditures

• For the three months ended January 2026, Conexeu Sciences reported capital expenditures of $0.01 million for the purchase of property, plant, and equipment.
• Funds raised from financing are intended to accelerate the development and commercialization of its patented collagen platform, specifically for 510(k) regulatory clearances and product development.